Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

BMC cancer - 12 Dec 2010

Olesen Uffe H, Petersen Jakob G, Garten Antje, Kiess Wieland, Yoshino Jun, Imai Shin-Ichiro, Christensen Mette K, Fristrup Peter, Thougaard Annemette V, Björkling Fredrik, Jensen Peter B, Nielsen Søren J, Sehested Maxwell

Abstract excerpt

BACKGROUND: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail. METHODS: Here, we introduce an analogue of CHS-828 called TP201565 with increased potency in cellular assays. Further, we describe and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Binding, Competitive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyanides

Share to Guanidines

Share to HCT116 Cells

Share to Inhibitory Concentration 50

Share to Nicotinamide Phosphoribosyltransferase

Share to Piperidines

Source

Open in PubMed Open full text

Identifiers

PMID: 21144000
DOI: 10.1186/1471-2407-10-677
PMCID: PMC3019212

Genes

NAMPT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.PMID 21144000Read ↗

Structural basis for resistance to diverse classes of NAMPT inhibitors.Semantic proximity Read ↗

Mechanisms of resistance to NAMPT inhibitors in cancerSemantic proximity Read ↗

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT InhibitorsSemantic proximity Read ↗

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.Semantic proximity Read ↗

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.Semantic proximity Read ↗

Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferaseSemantic proximity Read ↗

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA RepairSemantic proximity Read ↗

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug DiscoverySemantic proximity Read ↗

Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.Semantic proximity Read ↗

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.Semantic proximity Read ↗

NAMPT Is the Cellular Target of STF-31-Like Small-Molecule ProbesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.